Evidence map›Paper›PMID 36835525›Full record

ArticleInternational journal of molecular sciences2023

Impaired Organokine Regulation in Non-Diabetic Obese Subjects: Halfway to the Cardiometabolic Danger Zone.

Hajnalka Lőrincz, Balázs Ratku, Sára Csiha, Ildikó Seres, Zoltán Szabó, György Paragh, Mariann Harangi, Sándor Somodi

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Proteomic biomarkers of cognitive function,medRxiv : the preprint server for health sciences · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Hajnalka LőrinczDivision of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
Balázs RatkuDepartment of Emergency Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
Sára CsihaDivision of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
Ildikó SeresDivision of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
Zoltán SzabóDepartment of Emergency Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
György ParaghDivision of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
Mariann HarangiDivision of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.ORCID 0000-0001-9761-9595
Sándor SomodiDepartment of Emergency Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
University of Debrecen · HU

Funding

National Research, Development and Innovation Office - NKFIH K142273National Research, Development and Innovation Office - NKFIH PD124126
6 · The paper itself

Abstract

Altered organokine expression contributes to increased cardiometabolic risk in obesity. Our aim was to evaluate the associations of serum afamin with glucose homeostasis, atherogenic dyslipidemia, and other adipokines in severe obesity to clarify the early metabolic alterations. 106 non-diabetic obese (NDO) subjects and 62 obese patients with type 2 diabetes matched for age, gender, and body mass index (BMI) were enrolled in this study. We compared their data with 49 healthy, lean controls. Serum afamin and retinol-binding protein 4 (RBP4), as well as plasma plasminogen activator inhibitor-1 (PAI-1), were measured with ELISA, and lipoprotein subfractions were analyzed using Lipoprint gel electrophoresis. Afamin and PAI-1 found to be significantly higher in the NDO and T2M group (

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Insulin ResistanceBody Mass IndexGlucoseHumansObesityPlasminogen Activator Inhibitor 1Retinol-Binding Proteins, PlasmaGlucosePlasminogen Activator Inhibitor 1RBP4 protein, humanRetinol-Binding Proteins, Plasmaafamincardiometabolicinsulin resistancelipid metabolismlipoprotein subfractionobesityplasminogen-activator inhibitor-1retinol binding protein 4type 2 diabetes

Identifiers

PMID36835525
PMCPMC9963515
OpenAlexW4321374283

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.